Literature DB >> 25414480

Cardiac troponin levels following implantable cardioverter defibrillation implantation and testing.

Guy Furniss1, Bijia Shi2, Alejandro Jimenez1, Scott A Harding1, Peter D Larsen3.   

Abstract

AIMS: Previous studies have reported the defibrillation testing during implantable cardioverter defibrillator (ICD) implantation is associated with elevated cardiac biomarkers and ST-segment electrocardiogram (ECG) changes suggesting that shocks during testing may cause harm. However, the effects of testing have not been isolated from the implant procedure itself, where lead deployment may cause myocardial damage. This prospective study examined high sensitivity troponin T (hs-TnT) levels and ECG changes during ICD implanting alone, ICD implantation with testing and device testing as a stand-alone procedure. METHODS AND
RESULTS: We examined hs-TnT at baseline, and 6-8 h post procedure and 12 lead ECG at baseline, and 30 s, 5 min, and 10 min post right ventricle lead deployment and post defibrillation. There was no significant change in hs-TnT levels in a group of patients (n = 11) undergoing defibrillation testing alone, while hs-TnT was significantly elevated in patients undergoing implantation alone (n = 13, median increase 96%, P = 0.005) and in patients undergoing implantation and testing (n = 13, median increase 161%, P = 0.005). There was a significant correlation between the number of lead deployments and the percentage change in hs-TnT (r = -0.51, P = 0.01), but no correlation between either the number of shocks (r = 0.26, P = 0.25) or the total delivered energy (r = 0.24, P = 0.30) and percentage change in hs-TnT.
CONCLUSION: Implantation of ICD leads was associated with release of troponin, but we did not observe any evidence that ICD shocks alone cause myocardial injury. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2014. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Defibrillation testing; High sensitivity cardiac troponin T; Implantable cardioverter defibrillator

Mesh:

Substances:

Year:  2014        PMID: 25414480     DOI: 10.1093/europace/euu306

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  5 in total

1.  Acute Effects of Implantable Cardioverter-Defibrillator Shocks on Biomarkers of Myocardial Injury, Apoptosis, Heart Failure, and Systemic Inflammation.

Authors:  Jordan Brewster; Travis Sexton; Gary Dhaliwal; Richard Charnigo; Gustavo Morales; Kevin Parrott; Yousef Darrat; John Gurley; Susan Smyth; Claude S Elayi
Journal:  Pacing Clin Electrophysiol       Date:  2017-03-08       Impact factor: 1.976

2.  Biomarkers of Myocardial Injury and Inflammation after Permanent Pacemaker Implantation: The Lead Fixation Type Effect.

Authors:  Dimitrios Varvarousis; Nikolaos Goulas; Kali Polytarchou; Stavroula N Psychari; Konstantinos Paravolidakis; Agapi Konstantinidou; Dionysios Tsoukalas; Delia Vlad; Konstantina Bouki; Athanasios Kotsakis
Journal:  J Atr Fibrillation       Date:  2018-04-30

Review 3.  High-Sensitivity Troponin as a Biomarker in Heart Rhythm Disease.

Authors:  Cian P McCarthy; Omair Yousuf; Alvaro Alonso; Elizabeth Selvin; Hugh Calkins; John W McEvoy
Journal:  Am J Cardiol       Date:  2017-02-09       Impact factor: 2.778

4.  ICD Shock, Not Ventricular Fibrillation, Causes Elevation of High Sensitive Troponin T after Defibrillation Threshold Testing--The Prospective, Randomized, Multicentre TropShock-Trial.

Authors:  Verena Semmler; Jürgen Biermann; Bernhard Haller; Clemens Jilek; Nikolaus Sarafoff; Carsten Lennerz; Hrvoje Vrazic; Bernhard Zrenner; Stefan Asbach; Christof Kolb
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

5.  Pediatric defibrillation shocks alone do not cause heart damage in a porcine model.

Authors:  Ben McCartney; Adam Harvey; Amy Kernaghan; Sara Morais; Olibhéar McAlister; Paul Crawford; Pardis Biglarbeigi; Raymond Bond; Dewar Finlay; David McEneaney
Journal:  Resusc Plus       Date:  2022-02-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.